Peter C. Enzinger

24.8k citations

147 papers · 8.4k indexed · 3 hit papers · h-index 39

Impact in

Oncology top 0.5%
- Pancreatic and Hepatic Oncology Research
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
Pulmonary and Respiratory Medicine top 0.5%
- Gastric Cancer Management and Outcomes

Papers in

Oncology 96
- Colorectal Cancer Treatments and Studies 36
- Pancreatic and Hepatic Oncology Research 25
- Cancer Immunotherapy and Biomarkers 21
Pulmonary and Respiratory Medicine 98
- Gastric Cancer Management and Outcomes 74
- Lung Cancer Treatments and Mutations 28

Co-authors: Robert J. Mayer Charles S. Fuchs Jeffrey W. Clark David P. Ryan Jeffrey A. Meyerhardt Matthew H. Kulke Keith Stuart Lawrence S. Blaszkowsky
Journals: Journal of Clinical Oncology (63 papers)Annals of Oncology (23 papers)The Oncologist (5 papers)Cancer (4 papers)Future Oncology (4 papers)
Partner nations: United States Japan South Korea

In The Last Decade

Peter C. Enzinger

140 papers receiving 8.3k citations

Hit Papers

align trajectories log scale

Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial 2023 · 342 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2023 The Lancet
2018 JAMA Oncology
2003 New England Journal of Medicine

Peers

Countries citing papers authored by Peter C. Enzinger

Since Specialization

Citations

This map shows the geographic impact of Peter C. Enzinger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter C. Enzinger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter C. Enzinger more than expected).

Fields of papers citing papers by Peter C. Enzinger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter C. Enzinger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter C. Enzinger. The network helps show where Peter C. Enzinger may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Peter C. Enzinger, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Peter C. Enzinger Line = papers co-authored together Peter C. Enzinger links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Consensus guidance for prevention and management of nausea and vomiting in patients treated with zolbetuximab + chemotherapy: a RAND/UCLA modified Delphi panel study PubMed ·Samuel J. Klempner, Roberto Pazo-Cid, Sara Lonardi, 芦田貴志, Е.А. Бордаченкова, Peter C. Enzinger, Andrew H. Ko, Gina M. Vaccaro, Yum Joon Keun, Anwaar Saeed, K.-W. Lee, Kohei Shitara, David H. Ilson, Jaffer A. Ajani, 白鹏, Stéphanie Braun, Michael S. Broder, G. Zöller	2025	4
2	Genomic Landscape of Late-Stage Gastric Cancer: Analysis From KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Studies JCO Precision Oncology ·Yelena Y. Janjigian, Michael Cecchini, Kohei Shitara, Peter C. Enzinger, Zev A. Wainberg, Ian Chau, Taroh Satoh, Jeeyun Lee, Michael Nebozhyn, Andrey Loboda, Julie Kobie, Amir Vajdi, Chie‐Schin Shih, Răzvan Cristescu, Luisa Fernandez-Ford	2025	1
3	LBA79 Lenvatinib plus pembrolizumab and chemotherapy vs pembrolizumab and chemotherapy in untreated metastatic esophageal squamous cell carcinoma: The randomized phase III LEAP-014 study Annals of Oncology ·И. Т. Глебов, S-B. Kim, Takashi Ogata, Min Hee Hong, Ali Emrouznejad, Shun Yamamoto, Julia Kuznetsova, PraveenKumar Etta, Chin‐Yo Lin, Sang Cheul Oh, Sara Gallardo Trillo, Tao Deng, Ying Zhang, Peter C. Enzinger, Hanneke W. M. van Laarhoven, И В Макляев, Wei He, Beata Bińkowska-Artowicz, Manan Shah, Li Shen	2025	0
4	LEAP-014: first-line lenvatinib + pembrolizumab + chemotherapy in advanced/metastatic esophageal squamous cell carcinoma Future Oncology ·Jong‐Mu Sun, Antoine Adenis, Peter C. Enzinger, Manish A. Shah, Ken Kato, Jaafar Bennouna, Toshihiko Doi, Natalyn Hawk, Li Yu, Sukrut Shah, Pooja Bhagia, Lin Shen	2024	2
5	Final overall survival results from phase 3 SPOTLIGHT study evaluating zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients (pts) with claudin 18 isoform 2 (CLDN18.2)+, HER2−, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma. Journal of Clinical Oncology ·Kohei Shitara, Eric Van Cutsem, Florian Lordick, Peter C. Enzinger, David H. Ilson, Manish A. Shah, Rui‐Hua Xu, Sara Lonardi, Kensei Yamaguchi, zhiqi Li, Bożena Kukiełka-Budny, Angie R. Skelton, Maria Matsangou, Ran Li, Diarmuid Moran, Zhigao Zhai, J. Gardeazábal García, Jaffer A. Ajani	2024	4
6	Zolbetuximab plus chemotherapy for locally advanced unresectable or metastatic stomach or gastroesophageal junction cancers: a plain language summary Future Oncology ·Kohei Shitara, Manish A. Shah, Florian Lordick, Yung‐Jue Bang, David H. Ilson, Eric Van Cutsem, Peter C. Enzinger, Karl Menges, Samuel J. Klempner, Diarmuid Moran, Jung Wook Park, Débora Santos da SILVA, Jaffer A. Ajani, Rui‐Hua Xu	2024	1
7	Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial Gastric Cancer ·Zev A. Wainberg, Yoon‐Koo Kang, Keun‐Wook Lee, Shukui Qin, Kensei Yamaguchi, In‐Ho Kim, Anwaar Saeed, Sang Cheul Oh, Jin Li, Hacı Mehmet Türk, Alexandra Teixeira, Erika Hitre, Andre De Oliveira Nascimento, Giovanni Gerardo Cardellino, Chrisna Putra Buana, Anita Zahlten‐Kumeli, Kate Taylor, Peter C. Enzinger	2024	30
8	134MO Updated efficacy and safety results from phase III GLOW study evaluating zolbetuximab + CAPOX as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2−, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma Annals of Oncology ·Florian Lordick, Manish A. Shah, Kohei Shitara, Jaffer A. Ajani, Y-J. Bang, Peter C. Enzinger, David H. Ilson, Zubin Arora, Javier Gállego, Jee‐Fu Huang, Lin Shen, Sang Cheul Oh, Patrapim Sunpaweravong, Tomohiko, Hacı Mehmet Türk, J.W. Park, Diarmuid Moran, P. Bhattacharya, Yue Cao, NmgMe	2023	2
9	LBA82 Updated efficacy and safety results from phase III SPOTLIGHT study evaluating zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2−, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma Annals of Oncology ·Jaffer A. Ajani, Florian Lordick, Y-J. Bang, Peter C. Enzinger, David H. Ilson, Manish A. Shah, Eric Van Cutsem, NmgMe, Giuseppe Aprile, Jianming Xu, Roberto Pazo-Cid, Alexander E. Kochupalov, Jianke Yang, Diarmuid Moran, Prasun Bhattacharya, Maria Matsangou, Ahsan M. Arozullah, J.W. Park, Kohei Shitara	2023	0
10	Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric/gastroesophageal junction adenocarcinoma (FIGHT). Journal of Clinical Oncology ·Zev A. Wainberg, Peter C. Enzinger, Yoon‐Koo Kang, Kensei Yamaguchi, Shukui Qin, Keun‐Wook Lee, Sang Cheul Oh, Jin Li, Hacı Mehmet Türk, Alexandra Teixeira, Giovanni Gerardo Cardellino, G Aishvarya, Siddhartha Mitra, Yingsi Yang, Helen Collins, Daniel V.T. Catenacci	2021	63
11	KEYNOTE-975 Study Design: a Phase III Study of Definitive Chemoradiotherapy Plus Pembrolizumab in Patients with Esophageal Carcinoma Future Oncology ·Manish A. Shah, Jaafar Bennouna, Toshihiko Doi, Lin Shen, Ken Kato, Antoine Adenis, Harvey J. Mamon, Markus Moehler, Xiaolong Fu, Byoung Chul Cho, Sonal Bordia, Pooja Bhagia, Chie-Schin Shih, Anjali Desai, Peter C. Enzinger	2021	78
12	LBA8_PR Pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase 3 KEYNOTE-590 study Annals of Oncology ·Ken Kato, И. Т. Глебов, Manan Shah, Peter C. Enzinger, Antoine Adenis, Toshihiko Doi, Takashi Kojima, J-P. Metges, Zhouxiao Li, S-B. Kim, 健司光藤, Wasat Mansoor, SH Li, Patrapim Sunpaweravong, María Maqueda, Eray Goekkurt, 正則江藤, Sukrut Shah, Pooja Bhagia, Lin Shen	2020	98
13	The phase 3 KEYNOTE-181 study: pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer Annals of Oncology ·Jean‐Philippe Metges, Éric François, Manish A. Shah, Antoine Adenis, Peter C. Enzinger, Takashi Kojima, Kei Muro, Jaafar Bennouna, Chih‐Hung Hsu, Toshikazu Moriwaki, Sejoong Kim, Bimal Khandelwal, Ken Kato, Lin Shen, Shukui Qin, P. Ferreira, Indradeo Hemraj, Pooja Bhagia, Soonmo Peter Kang, Toshihiko Doi	2019	24
14	Phase II and Pharmacodynamic Study of Autophagy Inhibition Using Hydroxychloroquine in Patients With Metastatic Pancreatic Adenocarcinoma The Oncologist ·Brian M. Wolpin, Douglas A. Rubinson, Xiaoxu Wang, Jennifer A. Chan, James M. Cleary, Peter C. Enzinger, Charles S. Fuchs, Nadine J. McCleary, Jeffrey A. Meyerhardt, Kimmie Ng, Deborah Schrag, David Eduardo, Beverly Spicer, Noelia Morillo Gallego, Harvey J. Mamon, Alec C. Kimmelman	2014	289
15	Identification of Potentially Avoidable Hospitalizations in Patients With GI Cancer Journal of Clinical Oncology ·Gabriel A. Brooks, Thomas A. Abrams, Jeffrey A. Meyerhardt, Peter C. Enzinger, Gwenaëlle S. G. Géléoc, Rheinallt Llwyd., Hajime Uno, Joseph O. Jacobson, Charles S. Fuchs, Deborah Schrag	2014	120
16	Multicenter Phase II Study of Tivozanib (AV-951) and Everolimus (RAD001) for Patients With Refractory, Metastatic Colorectal Cancer The Oncologist ·Brian M. Wolpin, Kimmie Ng, Andrew X. Zhu, Thomas A. Abrams, Peter C. Enzinger, Nadine J. McCleary, Deborah Schrag, Eunice L. Kwak, Jill N. Allen, Pankaj Bhargava, Jennifer A. Chan, Wolfram Goessling, Lawrence S. Blaszkowsky, Jeffrey G. Supko, Tomas Goldberger, Kaori Sato, Eileen Regan, Jeffrey A. Meyerhardt, Charles S. Fuchs	2013	38
17	Prospective Study of Bevacizumab Plus Temozolomide in Patients With Advanced Neuroendocrine Tumors Journal of Clinical Oncology ·Jennifer A. Chan, Keith Stuart, Craig C. Earle, Jeffrey W. Clark, Pankaj Bhargava, Rebecca A. Miksad, Lawrence S. Blaszkowsky, Peter C. Enzinger, Jeffrey A. Meyerhardt, Hui Zheng, Charles S. Fuchs, Matthew H. Kulke	2012	207
18	Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma Cancer ·Andrew X. Zhu, Keith Stuart, Lawrence S. Blaszkowsky, Alona Muzikansky, Donald P. Reitberg, Jeffrey W. Clark, Peter C. Enzinger, Pankaj Bhargava, Jeffrey A. Meyerhardt, Kerry Horgan, Charles S. Fuchs, David P. Ryan	2007	190
19	A Phase II Trial of Irinotecan and Cisplatin in Patients with Metastatic Neuroendocrine Tumors Digestive Diseases and Sciences ·Matthew H. Kulke, Bingyan Wu, David P. Ryan, Peter C. Enzinger, Andrew X. Zhu, Jeffrey W. Clark, Craig C. Earle, Ann Michelini, Charles S. Fuchs	2006	68
20	A Phase II Study of Doxorubicin, Cisplatin, and 5-Fluorouracil in Patients with Advanced Adenocarcinoma of the Stomach or Esophagus Cancer Investigation ·Matthew H. Kulke, Bingyan Wu, Jeffrey W. Clark, Peter C. Enzinger, Thomas J. Lynch, Michele Vincitore, Ann Michelini, Charles S. Fuchs	2006	8

About Peter C. Enzinger

Peter C. Enzinger is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Gastroenterology, Surgery and Hepatology, having authored 147 papers that have together received 8.4k indexed citations. Recurring topics across this work include Gastric Cancer Management and Outcomes (74 papers), Esophageal Cancer Research and Treatment (48 papers), Colorectal Cancer Treatments and Studies (36 papers), Lung Cancer Treatments and Mutations (28 papers), Pancreatic and Hepatic Oncology Research (25 papers), Cancer Immunotherapy and Biomarkers (21 papers), Neuroendocrine Tumor Research Advances (13 papers) and Gastrointestinal Tumor Research and Treatment (11 papers). The work is most often cited by research in Oncology (4.2k citations), Pulmonary and Respiratory Medicine (3.5k citations), Gastroenterology (537 citations), Surgery (3.4k citations) and Cancer Research (1.1k citations). Peter C. Enzinger has collaborated with scholars based in United States, Japan and South Korea. Frequent co-authors include Robert J. Mayer, Charles S. Fuchs, Jeffrey W. Clark, David P. Ryan, Jeffrey A. Meyerhardt, Matthew H. Kulke, Keith Stuart, Lawrence S. Blaszkowsky, Andrew X. Zhu and Alona Muzikansky. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, The Oncologist, Cancer and Future Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact